Literature DB >> 22886659

RAF/MEK dependence of KRAS-mutant pancreatic ductal adenocarcinomas.

Aphrothiti J Hanrahan1, David B Solit.   

Abstract

Studies using genetically engineered mouse models indicate that RAF activation is sufficient to induce pancreatic intraepithelial neoplasms, suggesting that mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor-based combination approaches may have clinical use in patients with pancreatic ductal adenocarcinomas. Cancer Discov; 2(8); 666-9. ©2012 AACR.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22886659      PMCID： PMC5031078          DOI： 10.1158/2159-8290.CD-12-0308

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  11 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

2.  A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.

Authors:  Eric A Collisson; Christy L Trejo; Jillian M Silva; Shenda Gu; James E Korkola; Laura M Heiser; Roch-Philippe Charles; Brian A Rabinovich; Byron Hann; David Dankort; Paul T Spellman; Wayne A Phillips; Joe W Gray; Martin McMahon
Journal:  Cancer Discov       Date:  2012-05-24       Impact factor: 39.397

3.  Pten constrains centroacinar cell expansion and malignant transformation in the pancreas.

Authors:  Ben Z Stanger; Bangyan Stiles; Gregory Y Lauwers; Nabeel Bardeesy; Michael Mendoza; Ying Wang; Amy Greenwood; Kuang-hung Cheng; Margaret McLaughlin; Dennis Brown; Ronald A Depinho; Hong Wu; Douglas A Melton; Yuval Dor
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

4.  Key role of phosphoinositide 3-kinase class IB in pancreatic cancer.

Authors:  Charlotte E Edling; Federico Selvaggi; Richard Buus; Tania Maffucci; Pierluigi Di Sebastiano; Helmut Friess; Paolo Innocenti; Hemant M Kocher; Marco Falasca
Journal:  Clin Cancer Res       Date:  2010-09-28       Impact factor: 12.531

5.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

Authors:  Sunil R Hingorani; Lifu Wang; Asha S Multani; Chelsea Combs; Therese B Deramaudt; Ralph H Hruban; Anil K Rustgi; Sandy Chang; David A Tuveson
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

6.  A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.

Authors:  David Dankort; Elena Filenova; Manuel Collado; Manuel Serrano; Kirk Jones; Martin McMahon
Journal:  Genes Dev       Date:  2007-02-13       Impact factor: 11.361

7.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Authors:  Eric W Joseph; Christine A Pratilas; Poulikos I Poulikakos; Madhavi Tadi; Weiqing Wang; Barry S Taylor; Ensar Halilovic; Yogindra Persaud; Feng Xing; Agnes Viale; James Tsai; Paul B Chapman; Gideon Bollag; David B Solit; Neal Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-28       Impact factor: 11.205

8.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

9.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

Authors:  Sunil R Hingorani; Emanuel F Petricoin; Anirban Maitra; Vinodh Rajapakse; Catrina King; Michael A Jacobetz; Sally Ross; Thomas P Conrads; Timothy D Veenstra; Ben A Hitt; Yoshiya Kawaguchi; Don Johann; Lance A Liotta; Howard C Crawford; Mary E Putt; Tyler Jacks; Christopher V E Wright; Ralph H Hruban; Andrew M Lowy; David A Tuveson
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

10.  Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Authors:  David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg
Journal:  Nat Genet       Date:  2009-03-12       Impact factor: 38.330
View more
  8 in total

1.  IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis.

Authors:  Mihir Rajurkar; Kyvan Dang; Maite G Fernandez-Barrena; Xiangfan Liu; Martin E Fernandez-Zapico; Brian C Lewis; Junhao Mao
Journal:  Cancer Res       Date:  2017-01-09       Impact factor: 12.701

2.  LncRNA OIP5-AS1 promotes the malignancy of pancreatic ductal adenocarcinoma via regulating miR-429/FOXD1/ERK pathway.

Authors:  Liping Wu; Yongcun Liu; Cheng Guo; Yuan Shao
Journal:  Cancer Cell Int       Date:  2020-07-09       Impact factor: 5.722

3.  Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.

Authors:  Shinichi Yabuuchi; Shweta G Pai; Nathaniel R Campbell; Roeland F de Wilde; Elizabeth De Oliveira; Preethi Korangath; Mirte M Streppel; Zeshaan A Rasheed; Manuel Hidalgo; Anirban Maitra; N V Rajeshkumar
Journal:  Cancer Lett       Date:  2013-02-10       Impact factor: 8.679

Review 4.  Development of PI3K inhibitors: lessons learned from early clinical trials.

Authors:  Jordi Rodon; Rodrigo Dienstmann; Violeta Serra; Josep Tabernero
Journal:  Nat Rev Clin Oncol       Date:  2013-02-12       Impact factor: 66.675

5.  Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma.

Authors:  Zhou Luan; Ying He; Mohamed Alattar; Zhishui Chen; Fan He
Journal:  Mol Cancer       Date:  2014-02-25       Impact factor: 27.401

6.  Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.

Authors:  Niranjan Awasthi; Sheena Monahan; Alexis Stefaniak; Margaret A Schwarz; Roderich E Schwarz
Journal:  Oncotarget       Date:  2017-12-25

7.  Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer.

Authors:  Suhasini Joshi; Erica DaGama Gomes; Tai Wang; Adriana Corben; Tony Taldone; Srinivasa Gandu; Chao Xu; Sahil Sharma; Salma Buddaseth; Pengrong Yan; Lon Yin L Chan; Askan Gokce; Vinagolu K Rajasekhar; Lisa Shrestha; Palak Panchal; Justina Almodovar; Chander S Digwal; Anna Rodina; Swathi Merugu; NagaVaraKishore Pillarsetty; Vlad Miclea; Radu I Peter; Wanyan Wang; Stephen D Ginsberg; Laura Tang; Marissa Mattar; Elisa de Stanchina; Kenneth H Yu; Maeve Lowery; Olivera Grbovic-Huezo; Eileen M O'Reilly; Yelena Janjigian; John H Healey; William R Jarnagin; Peter J Allen; Chris Sander; Hediye Erdjument-Bromage; Thomas A Neubert; Steven D Leach; Gabriela Chiosis
Journal:  Commun Biol       Date:  2021-11-25

8.  CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis.

Authors:  Qiang Ding; Yumi Miyazaki; Koichiro Tsukasa; Shyuichiro Matsubara; Makoto Yoshimitsu; Sonshin Takao
Journal:  Mol Cancer       Date:  2014-01-27       Impact factor: 27.401
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.